ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AEMD
NMTC (33) PLSM (47) FEMY (30) ICU (31) ⌘ Pro Terminal →

Aethlon Medical Inc. (AEMD) — RQD Stock Rating Cockpit

$5.29 -2.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.25

Aethlon Medical Inc. (AEMD) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $8.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AEMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AEMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Aethlon Medical Inc. (NASDAQ: AEMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $5.29 (-2.76% 1D, market cap $8.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AEMD ranks #579 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AEMD compare to NMTC and PLSM in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), AEMD carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NMTC (NeuroOne Medical Technologies Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $8.4M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, AEMD leads on earnings multiple (N/A) while AEMD leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AEMD?
▼

Per AEMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0000882291), Aethlon Medical Inc. generated $20.4M in revenue (-21.9% YoY), -$7.2M in net income, and -$7.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.25 (-0.69%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (5)Whales (7)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.8% Base Target
$28 Bull$5 Base$4 Bear
📬 FREE AEMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AEMD)Realized 20D OHLCV Swing Band: ±11.7%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY AEMD SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (25% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 53.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$5.58-4.8% Next Q
Q2 (-2Q)
41
Grade D$5.31-4.5% Next Q
Q3 (-1Q)
39
Grade E$5.07+4.3% Next Q
Current
36
Grade D-$5.29-8.3% Hist 90D α
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AEMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AEMD currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.58) and Max Pain ($5.55) forces dealer call-delta covering toward $27.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AEMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AEMD Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
53.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE16% OF RANGE
L: $1$5.29H: $26
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 5 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on AEMD

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (25)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (35)

12/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like AEMD
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AEMD)

  • ✓Walkthrough of AEMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AEMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -55.92%▼ DESCENDING CHANNEL
2026-11-03O $5.52H $5.52L $5.29C $5.29VOL 27.7K
RES: $6.79SUP: $0.22SMA50: $4.58SMA200: $7.69
$28.74$21.33$13.92$6.52$-0.89RES $6.79SUP $0.22$5.292026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AEMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AEMD Butterfly Map → + Track AEMD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -21.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AEMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AEMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AEMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AEMD)

Health Care Rank #579 of 1015 ⚔️ NMTC vs AEMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AEMD vs. NMTC, PLSM, FEMY, ICU)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Aethlon Medical Inc. (AEMD) ranks #579 by composite RQD confidence (36/100, grade D-) and #904 by equity capitalization ($8.7M). Within this direct 5-issuer industry benchmark cohort, AEMD leads on earnings valuation at N/A trailing P/E, while AEMD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PLSM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with AEMD at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AEMD ACTIVE
Aethlon Medical Inc.
D- 36/100 — — -35.0% -2.76% $8.7M Benchmark Subject
NMTC
NeuroOne Medical Technologies Corporation
E 33/100 — 56.5% -35.0% +0.82% $8.4M /nmtc-vs-aemd →
PLSM
Pulsenmore Ltd.
D 47/100 — — — -1.87% $10.9M /plsm-vs-aemd →
FEMY
Femasys Inc.
E 30/100 — 62.0% -35.0% -3.65% $11.5M /femy-vs-aemd →
ICU
SeaStar Medical Holding Corporation
E 31/100 — 95.7% -35.0% -2.23% $11.8M /icu-vs-aemd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0000882291 ↗

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Aethlon Medical Inc. (AEMD) reported GAAP revenue of $20.4M (-21.9% vs. FY2024 revenue of $26.2M , and -42.3% cumulative change since FY2023) , GAAP net income of -$7.2M, operating cash flow of -$7.0M, and free cash flow of -$7.0M (+8.4% YoY). On the balance sheet, AEMD closed FY2025 with $8.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-03-31 $20.4M -$7.2M -$7.0M -$7.0M $8.1M —
FY2024 (FY) 2025-03-31 $26.2M -$13.4M -$7.6M -$7.6M $6.5M —
FY2023 (FY) 2024-03-31 $35.4M -$12.2M -$10.1M -$10.1M — —

3. AEMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AEMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Aethlon Medical Inc. (NASDAQ: AEMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $5.29 (-2.76% 1D, market cap $8.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, AEMD ranks #579 in composite RQD confidence.

How does AEMD compare to NMTC and PLSM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), AEMD carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NMTC (NeuroOne Medical Technologies Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $8.4M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, AEMD leads on earnings multiple (N/A) while AEMD leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AEMD?

Per AEMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0000882291), Aethlon Medical Inc. generated $20.4M in revenue (-21.9% YoY), -$7.2M in net income, and -$7.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AEMD trading relative to its 50-day, 200-day, and 52-week technical levels?

AEMD last traded at $5.29 (-2.76% on volume of 112,192 shares), positioning the stock +15.50% above its 50-day simple moving average ($4.58) and -31.21% below its 200-day simple moving average ($7.69). Across its 52-week range of $1.41 to $26.20, AEMD sits at the 15.7% percentile with a 14-day RSI of 53.2 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($4.67 to $5.91).

Direct Sub-Reports: AEMD RQD Cockpit AEMD 12M Forecast AEMD Earnings & Move AEMD Dividends & DRIP AEMD Insiders & 13F AEMD Whale Options AEMD Profit Sankey AEMD News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ SEC XBRL & RQD VERIFIED

AEMD — Aethlon Medical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-03-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Aethlon Medical Inc. (AEMD) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $5.29 (-2.76% 1D, market capitalization $8.7M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Aethlon Medical Inc. (AEMD) is a NASDAQ-listed issuer in the Health Care sector, Medical/Dental Instruments industry (per the company profile). The profile does not describe its products, customers, or revenue model. Reported revenue is — across FY 2023 through FY 2025. Its market capitalization is $0.0B on the profile basis, while the market data section reports $8.9M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), Aethlon Medical Inc. (AEMD) reported $20.4M in annual revenue (up from $26.2M in FY2024, -21.9% YoY) and -$7.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($35.4M revenue, -$12.2M net income) through FY2025, AEMD scaled operating cash flow to -$7.0M and free cash flow to -$7.0M, backed by $8.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $1.41 – $26.20 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The sector is Health Care and the industry is Medical/Dental Instruments, but no peer or correlation data is provided. Investors should note that the absence of mapped links means ripple effects cannot be assessed from this dataset.

  • Key Question #1: Can AEMD sustain or expand its — operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $20.4M and free cash flow of -$7.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is AEMD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AEMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aethlon Medical Inc. (AEMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AEMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AEMD Bull vs. Bear Conversation Board — What's Your Call at $5.29?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AEMD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AEMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $6.85 (+25.9%)
📌 Pinned Debate

The forensic balance sheet pillar scores highest at 10 / 20, with Altman Z 2.5 and Debt/Equity 0.5, and cash rose to $7.0M in FY 2025 a

Long AEMD at $5.44 targeting $6.85. The forensic balance sheet pillar scores highest at 10 / 20, with Altman Z 2.5 and Debt/Equity 0.5, and cash rose to $7.0M in FY 2025 as operating losses narrowed.. Institutional whale score is 7/20 and the risk/reward vs. the $1.41 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $4.68 (-14.0%)
Spot @ $5.44

With zero revenue, ROIC of -35%, and FCF of -$7.0M against $7.0M cash, the company is burning its cash reserves while institutional and

Fading this rally in AEMD at $5.44. With zero revenue, ROIC of -35%, and FCF of -$7.0M against $7.0M cash, the company is burning its cash reserves while institutional and insider pillars score only 9 and 5 out of 20.. With a beta of 1.0 and the stock sitting at $5.44 (52-wk range $1.41–$26.20), the easy multiple expansion is already priced in.

LIVE TAPE